教育经历
工作经历
获得奖项
研究方向
科研项目
课程讲授
学术兼职
代表性论著
代表性专利
1995.09—2000.07 安徽医科大学临床医学专业本科生
2008.09—2012.07 复旦大学生物化学与分子生物学专业博士研究生
2000.07—2008.10 复旦大学基础医学院助教
2008.11—2014.10 复旦大学基础医学院讲师
2014.11—2020.10 复旦大学基础医学院副教授，期间在德克萨斯医学中心访学
2020.11—至今 复旦大学基础医学院教授
2014，“Reach the world”award，国际血栓与止血协会ISTH
2002，上海医学科技二等奖，上海市医学会
血小板激活机制和抗血栓药物临床转化
肿瘤早期标志物筛选和治疗靶点临床转化
遗传性疾病发病和治疗靶点临床转化
2021，上海市自然科学基金面上项目，“Baz蛋白调控血小板细胞骨架重构和活化的研究”，主持
2018，国家自然科学基金面上项目，“细胞极性蛋白Pard3在血小板中的表达和功能研究”，主持
2016，国家自然科学基金面上项目，“核受体FXR在无核血小板中的表达和功能”，主持
2012，国家自然科学基金青年项目，“P2Y12 受体激活抗血小板凋亡的机制研究”，主持
本科生课程：
分子生物学原理、正常人体形态与功能学概论、生物化学
研究生课程：
生物化学实验
2021-今 Frontiers in pharmocology 客座副主编
Fuing Chen#, Cheng Ni#, Xiaoxiao Wang#, Ruhong Cheng#, Chaolan Pan#, Yumeng Wang, Jianying Liang, Jia Zhang, Jinke Cheng, Y Eugene Chin, Yi Zhou, Zhen Wang, Yiran Guo, She Chen, Stephanie Htun, Erin F. Mathes, Alejandra G. de Alba Campomanes, Anne M. Slavotinek, Si Zhang（通讯）*, Ming Li1,*and Zhirong Yao*. S1P Defects Cause a New Entity of Cataract, Alopecia, Oral Mucosal Disorder, and Psoriasis-like Syndrome. Embo Molecular Medicine. 2022; e14904. doi: 10.15252/emmm.202114904. IF=12
Wang, Biyun; Zhao, Yannan; Li, Yi; Xu, Yingying; Chen, Yun; Jiang, Qiuyu; Yao, Dingjin; Z hang, Li; Hu, Xichun; Fu, Chaowei*; Zhang, Si（通讯）*; Chen, She* ; A plasma SNORD33 signature predicts pla tinum beneft in metastatic triple-negative breast cancer patients, Molecular Cancer, 2022, 21(1): 22. IF=27
Chen, Yufei; Fu, Wanrong; Zheng, Yunbo; Yang, Jing; Liu, Yangyang; Qi, Zhiyong; Wu, Meili ng; Fan, Zhichao; Yin, Kanhua; Chen, Yunfeng; Gao, Wen; Ding, Zhongren; Dong, Jianzeng; Li, Qi*; Zhang, Si（通讯）*; Hu, Liang* ; Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activa tion: a translational study, European Heart Journal, 2022, 00: 1-19. IF=30
Yi Zhou, Liang Hu, Wenqing Tang, Dongping Li, Lijie Ma, Hongchun Liu, Shuncai Zhang, Xiaojie Zhang, Ling Dong, Xizhong Shen, She Chen*, Ruyi Xue* and Si Zhang(通讯)*. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. Journal of hematology & oncology. 2021 14(8) 1-19. IF=17
Xinyi Liu, Yanjie Chen, Si Zhang （通讯）*& Ling Dong. Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research, 2021, 40(1): 1-20. IF=11
Si Zhang*(通讯), Yangyang Liu, Xiaofang Wang, Li Yang, Haishan Li, Yuyan Wang, Mengduan Liu, Xiaoyan Zhao, Youhua Xie, Yan Yang, Shenghui Zhang, Zhichao Fan, Jianzeng Dong, Zhenghong Yuan, Zhongren Ding, Yi Zhang* & Liang Hu*. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of hematology & oncology, 2020，13(1), 1-22. SCI; IF=17
Pingping Dong，Xiaoxiao Wang，Longzi Liu，Wenqing Tang，Lijie Ma，Wenjiao Zeng，Shaoyang Sun，Li Zhang，Ningping Zhang，Xizhong Shen，Harry L.A. Janssen，Ling Dong*，Si Zhang*（通讯）， She Chen* . Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma. Journal of Hepatology. 2020, 73(6), 1446-1459. IF=20.58
Si Zhang，Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei Chen,Guanjun Cheng, Jozef Mruk， SP Kunapuli, Zhongren Ding. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and Thrombosis. Circulation, 2015. 131(13):1160-70. IF=23
Liu, Xijun; Xue, Ruyi; Yang, Caiting; Gu, Jianxin; Chen, She*; Zhang, Si（通讯）* ; Cholestasis-ind uced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estro gen sulfotransferase SULT1E1. Journal of Biological Chemistry, 2018, 293(33): 12759-12769
Cai, Yu; Huang, Guanqun; Ma, Lijie; Dong, Ling; Chen, She; Shen, Xizhong; Zhang, Shuncai; Xue, Ruyi*; Sun, Deqiang*; Zhang, Si （通讯）*; Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and att enuates liver fibrosis through miR-132 mediated CTGF inhibition. Biochimica et Biophysica Acta-Molecular Cell Research, 2018, 1865(2): 297-308
小核仁核糖核酸SNORD33作为生物标记物用于制备检测试剂盒中的用途 (申请：CN201811173295.7）
模式识别受体TREM2在肝癌预后和治疗中的应用（申请：CN201810840310.2）
FXR激动剂在制备治疗脂肪肉瘤相关疾病药物中的用途（已授权：ZL201710204000.7）
BF061固体分散体及其制备方法和在制药中的用途（已授权：CN108338974B）
肿瘤血管破坏剂DMXAA在制备抗血小板、抗血栓药物中的用途（已授权：CN103800317B）
